Table 2.

Clinical Responses to Combination Therapy with 5F9 and Rituximab.^*

Response	All Patients (N = 22)	Patients with DLBCL (N = 15)	Patients with Follicular Lymphoma (N = 7)
Objective response	11 (50)	6 (40)	5 (71)
Complete response	8 (36)	5 (33)	3 (43)
Partial response	3 (14)	1 (7)	2 (29)
Stable disease	3 (14)	3 (20)	0
Progressive disease	8 (36)	6 (40)	2 (29)
Disease control	14 (64)	9 (60)	5 (71)

^*Objective response was defined as a complete or partial response. Disease control was defined as a complete response, partial response, or stable disease.